CLDN2 and breast carcinoma: We next assessed the association of Claudin-2 and Afadin expression either alone or in combination with four breast cancer end points: breast cancer-specific survival (BCSS), relapse-free survival (RFS), liver metastasis-free survival (LiMFS), or lung metastasis-free survival (LuMFS).